** Shares of Australian Clinical Labs ACL.AX rise as much as 5.1% to A$2.66, marking their highest level since September 4** Pathology services provider announces a new 12-month on-market share buyback programme of up to 19.5 million shares** Stock last up nearly 2% at A$2.58, on track for best day since October 16** YTD, ACL down 25.3%
(Reporting by Jasmeen Ara Shaikh)
((Jasmeenaraislam.shaikh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.